Here are four things to know.
1. Biktarvy is a once-daily, triple-combination tablet used to treat HIV infections.
2. The drug’s wholesale price will be about $36,000 per year, which falls in line with prices of other HIV treatments on the market.
3. Biktarvy contains a boxed warning about exacerbating hepatitis B infections in some patients.
4. ViiV Healthcare filed a lawsuit shortly after Biktarvy’s approval, claiming the drug infringed on patents for its own triple-drug HIV treatment.
More articles on supply chain:
Celgene Executive Chairman Bob Hugin abruptly steps down: 5 things to know
As flu rages throughout Florida, Tamiflu supplies run low
Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
